Cancer-associated_cachexia

A Novel Mouse Model to Identify Antigen-Specific Immune Responses in Pancreatic Cancer Cachexia.

BACKGROUND

Pancreatic Ductal Adenocarcinoma (PDAC) has a dismal five-year survival rate of 13% and is closely associated with cachexia. Cancer cachexia is a multifactorial syndrome characterized by irreversible wasting of skeletal muscles, fat loss and systemic inflammation. While cachexia is known...

🗓️ 2026-02-27
Read MoreA Novel Mouse Model to Identify Antigen-Specific Immune Responses in Pancreatic Cancer Cachexia.

The Role of New Agents and Supportive Care in a Multimodal Approach to Cancer Cachexia.

Given the multi-faceted nature of cancer cachexia, a combination of pharmacologic and supportive measures such as exercise and nutrition seems intuitive to most clinicians. Clinical trials have also suggested that a multimodal approach to cancer cachexia (CC) is feasible and...

🗓️ 2026-02-27
Read MoreThe Role of New Agents and Supportive Care in a Multimodal Approach to Cancer Cachexia.

Mitochondrial Permeability Transition in Skeletal Muscle Phenocopies Muscle Alterations seen in Cancer Cachexia and other Wasting Conditions.

BACKGROUND

Skeletal muscle in wasting conditions often exhibits a common set of phenotypes that include atrophy, mitochondrial respiratory dysfunction, and fragmentation of the acetylcholine receptor (AChR) cluster at the endplate. Mitochondria are frequently implicated in driving muscle pathology in these conditions,...

🗓️ 2026-02-23
Read MoreMitochondrial Permeability Transition in Skeletal Muscle Phenocopies Muscle Alterations seen in Cancer Cachexia and other Wasting Conditions.

High Fat Diet and Obesity Each Increase Tumor Cell Proliferation and Muscle Wasting in Experimental Cancer Cachexia.

High fat diet (HFD) and associated obesity are suggested to predispose to cancer development, complicate cancer treatment, and accelerate mortality. Paradoxically, obese patients with lung cancer are reported to live longer, suggesting that high body mass is protective. Given that...

🗓️ 2026-02-21
📰 Publication: American Journal Of Physiology-Cell Physiology
Read MoreHigh Fat Diet and Obesity Each Increase Tumor Cell Proliferation and Muscle Wasting in Experimental Cancer Cachexia.

Human neuromuscular organoids mimic cancer-induced muscle cachexia.

Cancer cachexia, a devastating metabolic wasting syndrome affecting up to 80% of solid cancer patients, remains incurable despite advances in tumor biology understanding. This study introduces neuromuscular organoids (NMOs) derived from human-induced pluripotent stem cells (hiPSCs) as a platform to...

🗓️ 2026-02-19
Read MoreHuman neuromuscular organoids mimic cancer-induced muscle cachexia.

Cancer Cachexia Prevalence Is Underestimated in Medical Records of Patients in a Regional Tertiary Hospital.

BACKGROUND

Widespread lack of awareness and limited real-world prevalence evidence have impeded cachexia care and research. We hypothesized that healthcare professionals may identify the term cachexia, leading to International Classification of Diseases (ICD) coding for this term, with or without records...

🗓️ 2026-02-18
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreCancer Cachexia Prevalence Is Underestimated in Medical Records of Patients in a Regional Tertiary Hospital.

Cancer cachexia in STK11/LKB1-mutated non-small cell lung cancer is dependent on tumor-secreted GDF15.

Cachexia is a wasting syndrome involving adipose, muscle, and body weight loss in cancer patients. Tumor loss-of-function mutations in STK11/LKB1, a regulator of AMP-activated protein kinase, induce cancer cachexia (CC) in preclinical models and are linked to weight loss in...

🗓️ 2026-01-31
📰 Publication: Nature Communications
Read MoreCancer cachexia in STK11/LKB1-mutated non-small cell lung cancer is dependent on tumor-secreted GDF15.

The gut microbiome and dietary interventions in cancer cachexia.

PURPOSE OF REVIEW

The gut microbiome (GM) is altered in cancer cachexia, and it is possible that such GM changes may promote or sustain features of cancer cachexia including changes in host metabolism and anorexia. As a result, there is growing...

🗓️ 2026-01-29
📰 Publication: Current Opinion In Clinical Nutrition And Metabolic Care
Read MoreThe gut microbiome and dietary interventions in cancer cachexia.

Distinct Metabolomic Alterations Are Associated With Physical Function, Weight Loss, and Muscle Mass in Men With Cancer.

BACKGROUND

Treatments for cancer cachexia, defined as involuntary weight and muscle mass loss leading to significant functional impairment, remain unavailable partly due to insufficient improvement of clinically meaningful outcomes in current trials. By reflecting downstream effects of cellular function, metabolomics may...

🗓️ 2026-01-19
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreDistinct Metabolomic Alterations Are Associated With Physical Function, Weight Loss, and Muscle Mass in Men With Cancer.

Tumor intrinsic properties dictate Fc receptor expression and cancer cachexia associated increase in checkpoint inhibitor clearance.

PURPOSE

Patients with cancer cachexia display a general resistance to immune checkpoint inhibitor (ICI) therapy, and baseline ICI catabolic clearance is a predictive indicator for overall survival, independent of dose and drug exposure. Fc-gamma (FcγRs) and neonatal Fc receptors (FcRn) play...

🗓️ 2026-01-02
📰 Publication: Frontiers In Immunology
Read MoreTumor intrinsic properties dictate Fc receptor expression and cancer cachexia associated increase in checkpoint inhibitor clearance.

CXCL5 neutralization mitigates cancer cachexia by disrupting CAF-cancer cell crosstalk.

BACKGROUND

Advanced metastasis produces cachexia, a complex skeletal muscle wasting syndrome that accounts for one-third of patient deaths. There is currently no approved drug therapy for cancer cachexia. Cancer-associated fibroblasts (CAF) within tumors have been hypothesized to contribute to cachexia, but...

🗓️ 2025-12-15
📰 Publication: Journal Of Biomedical Science
Read MoreCXCL5 neutralization mitigates cancer cachexia by disrupting CAF-cancer cell crosstalk.

Exploring the potential of ginseng-derived compounds in treating cancer cachexia.

Cancer cachexia is a complex wasting syndrome characterized by significant loss of body weight and muscle mass in patients with advanced cancer. The disease is associated with increased systemic inflammation, altered neurohormonal signaling, and, in particular, an increased catabolic rate...

🗓️ 2025-11-21
📰 Publication: Journal Of Ginseng Research
Read MoreExploring the potential of ginseng-derived compounds in treating cancer cachexia.

Revisiting Cancer Cachexia Staging: Introducing an "At Risk" Category Based on AWGC Components.

Cancer cachexia is a multifactorial syndrome characterized by progressive weight loss, muscle wasting, and systemic inflammation. Early identification of individuals at risk for cachexia is essential for timely intervention, yet a universally accepted definition of the "at risk" stage remains...

🗓️ 2025-11-20
📰 Publication: Thoracic Cancer
Read MoreRevisiting Cancer Cachexia Staging: Introducing an "At Risk" Category Based on AWGC Components.

The canonical ER stress IRE1α/XBP1 pathway mediates skeletal muscle wasting during pancreatic cancer cachexia.

Cancer cachexia is a debilitating syndrome characterized by the progressive loss of skeletal muscle mass with or without fat loss. Recent studies have implicated dysregulation of the endoplasmic reticulum (ER) stress-induced unfolded protein response (UPR) pathways in skeletal muscle under...

🗓️ 2025-11-18
📰 Publication: Embo Molecular Medicine
Read MoreThe canonical ER stress IRE1α/XBP1 pathway mediates skeletal muscle wasting during pancreatic cancer cachexia.

Impaired cAMP-PKA-CREB1 signalling drives mitochondrial dysfunction in skeletal muscle during cancer cachexia.

Skeletal muscle wasting is a defining feature of cancer cachexia, a multifactorial syndrome that drastically compromises patient quality of life and treatment outcomes. Mitochondrial dysfunction is a major contributor to skeletal muscle wasting in cancer cachexia, yet the upstream molecular...

🗓️ 2025-11-13
Read MoreImpaired cAMP-PKA-CREB1 signalling drives mitochondrial dysfunction in skeletal muscle during cancer cachexia.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!